US OptionsDetailed Quotes
CTXR250117P7500
- 0.00
- 0.000.00%
15min DelayClose Jan 10 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest7.50Strike Price0.00Turnover0.00%IV-106.61%PremiumJan 17, 2025Expiry Date3.87Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.94Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Citius Pharmaceuticals Stock Discussion
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment
PR Newswire· 4 mins ago
Citius Pharmaceuticals and Citius Oncology Highlight LYMPHIR Commercial Launch Planned for the First Half of 2025
Tuesday, 7th January at 8:08 am
CRANFORD, N.J., Jan. 7, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ: CTXR) and its oncology-focused subsidiary, Citius Oncology (NASDAQ: CTOR), today announced significant progress in preparations for the commercial launch of LYMPHIR™, an i...
The engagement of Jefferies as a financial advisor is a strategically significant move that could reshape Citius Oncology's future. Jefferies' strong track record in healthcare M&A and their expertise in orchestrating deals averaging $500M-$2B in the biotech sector positions them well to explore value-maximizing opportunities. With LYMPHIR™ recently FDA-approved and ready for commercialization, the timing aligns perfectly with...
Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives
Monday, 6th January at 7:50 am
CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (NASDAQ: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (NASDAQ: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategi...
Citius Pharmaceuticals Inc - Regains Compliance With Nasdaq Listing Rule 5550(a)(2)
might pull from this, let's see tonight!
No comment yet